Open-data contest unearths scientific gems — and controversy

"Now one-third of the 60 papers that Wright's team had planned to publish are in jeopardy of being scooped. “I think the incentives to do these trials will be dramatically lessened if this is going to be the expectation going forward,” he says. “It's a huge time commitment.”

But others favour making data from trials publicly available as soon as possible. Doing so, they argue, opens up the possibility of a wide range of additional analysis, and speeds up analyses that can yield important clinical insights. “Clinical trial data are quite valuable, but usually they're kept locked away,” says Sandosh Padmanabhan, a participant in the competition who researches cardiovascular genomics at the University of Glasgow, UK. “Everybody who does clinical trials needs to open up their data for everybody to use.”"

Thursday, June 16, 2016

Mr. Modi, Don't Patent Cow Urine; New York Times, 6/16/16

Achal Prabhala and Sudhir Krishnaswamy, New York Times; Mr. Modi, Don't Patent Cow Urine:

"The B.J.P. government released India’s first National Intellectual Property Rights Policy last month, and it is dangerously misguided. Although the paper reaffirms the basic tenets of India’s admirably farsighted patent laws, it also calls for protecting traditional remedies like cow urine. Taken to its logical conclusion, this policy could open the door to many more exceptions, playing into the hands of patent-happy international pharmaceutical companies.
Big Pharma justifies aggressive patenting by claiming that profit-making drives invention by giving labs and companies an incentive to invest in research. Indian law takes the opposite view: Higher standards for legal protection leave more room for innovation. Unlike many other countries, India does not allow patents for natural substances, traditional remedies, frivolous inventions or marginal innovations.
This is a good thing — a great thing, in fact. Having fewer patents means more competition for more generic drugs, which means more affordable medicine for more people. Imatinib, a drug used to treat a form of leukemia, is available in India at about one-tenth the price it costs in much of the world. In 2000, when the only anti-retroviral drugs for HIV/AIDS available were produced by Western companies, the annual cost of treatment was about $10,000. The price has dropped to about $350, at least in the developing world, thanks to generic equivalents that were developed in India.
Naturally, all this drives Big Pharma mad. Its business model relies largely on patenting small tweaks to existing technologies, which multiplies financial returns with only minimal investment in research."